Javascript must be enabled to continue!
GW24-e1764 Speckle Tracking Imaging Combined with High Sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity during Anthracycline-based Chemotherapy
View through CrossRef
Objectives
To detect the early subclinical myocardial injury during and shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma by two-dimensional speckle tracking imaging and high sensitive cardiac troponin T (hs-cTnT) and to investigate whether alterations of myocardial strains and high sensitive cardiac troponin T could predict future cardiac dysfunction in patients after epirubicin exposure.
Methods
Seventy-five patients aged 53.9 ± 13.8 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with anthracycline were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion. After 4–6 months of chemotherapy, echocardiography was followed up. Levels of cTnT were detected with a highly sensitive assay. Longitudinal (LS), circumferential (CS) and radial strain (RS) were calculated using two-dimensional speckle tracking echocardiography. Left ventricular ejection fraction (LVEF) was analysed by real-time 3D echocardiography. Cardiotoxicity was defined according to the guidelines (Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity, CREC) as a reduction of the left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%.
Results
LVEF remained stable and within normal limits in the whole course of chemotherapy. However it was decreased from 65.0 ± 3.8% at baseline to 60.8 ± 4.9% during follow-up (p = 0.000). Fourteen patients (18.67%) developed cardiotoxicity 4–6 months after treatment. Global LS (-18.5 ± 1.7% vs -16.5 ± 1.9%), CS (-20.9 ± 2.9% vs -19.3 ± 3.5%), RS (39.2 ± 6.4% vs 35.3 ± 5.2%) were markedly reduced and cTnT was elevated from 0.0010 ± 0.0020 ng/ml to 0.0063 ± 0.0089 ng/ml (p all<0.01) at the completion of the third cycle of chemotherapy compared with baseline values. The correlation between the increment of cTnT levels and percentage of global LS deduction was good (rho = 0.60, p < 0.01), and percentage of CS and RS decrease was modest (rho = 0.31, -0.29, respectively, p all <0.01). A >15.9% decrease in longitudinal strain ( sensitivity: 86%, specificity: 75%, AUC = 0.815, P = 0.001) and a >0.004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%, AUC = 0.757, P = 0.005) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity. The decrease of longitudinal strain between baseline and the third cycle of chemotherapy remained the only independent predictor of cardiotoxicity (p = 0.000).
Conclusions
Two-dimensional speckle tracking imaging combined with high sensitive cTnT may provide a reliable and accurate non-invasive method to detect subtle myocardial injury and to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy. The decrease of longitudinal strain is the only independent predictor of cardiotoxicity.
Title: GW24-e1764 Speckle Tracking Imaging Combined with High Sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity during Anthracycline-based Chemotherapy
Description:
Objectives
To detect the early subclinical myocardial injury during and shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma by two-dimensional speckle tracking imaging and high sensitive cardiac troponin T (hs-cTnT) and to investigate whether alterations of myocardial strains and high sensitive cardiac troponin T could predict future cardiac dysfunction in patients after epirubicin exposure.
Methods
Seventy-five patients aged 53.
9 ± 13.
8 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with anthracycline were studied.
Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion.
After 4–6 months of chemotherapy, echocardiography was followed up.
Levels of cTnT were detected with a highly sensitive assay.
Longitudinal (LS), circumferential (CS) and radial strain (RS) were calculated using two-dimensional speckle tracking echocardiography.
Left ventricular ejection fraction (LVEF) was analysed by real-time 3D echocardiography.
Cardiotoxicity was defined according to the guidelines (Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity, CREC) as a reduction of the left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%.
Results
LVEF remained stable and within normal limits in the whole course of chemotherapy.
However it was decreased from 65.
0 ± 3.
8% at baseline to 60.
8 ± 4.
9% during follow-up (p = 0.
000).
Fourteen patients (18.
67%) developed cardiotoxicity 4–6 months after treatment.
Global LS (-18.
5 ± 1.
7% vs -16.
5 ± 1.
9%), CS (-20.
9 ± 2.
9% vs -19.
3 ± 3.
5%), RS (39.
2 ± 6.
4% vs 35.
3 ± 5.
2%) were markedly reduced and cTnT was elevated from 0.
0010 ± 0.
0020 ng/ml to 0.
0063 ± 0.
0089 ng/ml (p all<0.
01) at the completion of the third cycle of chemotherapy compared with baseline values.
The correlation between the increment of cTnT levels and percentage of global LS deduction was good (rho = 0.
60, p < 0.
01), and percentage of CS and RS decrease was modest (rho = 0.
31, -0.
29, respectively, p all <0.
01).
A >15.
9% decrease in longitudinal strain ( sensitivity: 86%, specificity: 75%, AUC = 0.
815, P = 0.
001) and a >0.
004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%, AUC = 0.
757, P = 0.
005) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity.
The decrease of longitudinal strain between baseline and the third cycle of chemotherapy remained the only independent predictor of cardiotoxicity (p = 0.
000).
Conclusions
Two-dimensional speckle tracking imaging combined with high sensitive cTnT may provide a reliable and accurate non-invasive method to detect subtle myocardial injury and to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy.
The decrease of longitudinal strain is the only independent predictor of cardiotoxicity.
Related Results
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Abstract
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-induced cardiotoxicity effectively. In this study, we aimed to (1)...
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Abstract
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-induced cardiotoxicity effectively. In this study, we aimed to (1)...
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Abstract
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-induced cardiotoxicity effectively. In this study, we aimed to (1)...
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Bioinformatic Analysis of Peripheral Blood miRNA of Breast Cancer Patients in Relation With Anthracycline Cardiotoxicity
Abstract
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-induced cardiotoxicity effectively. In this study, we aimed to (1)...
Risk Factors for Anthracycline-Induced Cardiotoxicity
Risk Factors for Anthracycline-Induced Cardiotoxicity
Background: Several cardiovascular risk factors have been suggested to be associated with anthracycline-induced cardiotoxicity, but their quantitative effects have not reached a co...
Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity
Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity
Abstract
Background
The current diagnostic methods and treatments still fail to lower the incidence of anthracycline-indu...
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract P1-13-11: Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
Abstract
[Background]In adjuvant settings of HER2 positive cancer, trastuzumab has been shown to be effective in combination with anthracycline- based chemotherapy f...

